Dr. Abhishek Reddy and Dr. Joe Fuhrman stop by Houston Life to discuss their innovative approach to pain management.

“I believe JOURNAVX could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

While more work is needed to clarify a role for these options in pain management, their reward might be greater ... Only last month, the FDA approved the use of a new medication Journavx for managing ...

In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the battlefield, required no strong painkillers to manage their pain. In some ...

Vertex expects Journavx will be added to the Non-Opioids ... The measure increases access to non-opioid approaches to pain management in the hospital setting for those enrolled in Medicare.